What this means
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Completed
- Who can join
- Ages 60–90
- Where
- 1 site
The science
- Registered title
- Senolytics to Improve Osteoporosis Therapy
- Trial ID
- NCT06018467 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Osteopenia, Osteoporosis, Age-related Bone Loss
- What is tested
- Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral)
- Sponsor
- Odense University Hospital
- Ages
- 60 Years to 90 Years
- Dates
- First posted Aug 30, 2023 · updated Oct 23, 2026
Registry summary
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
Sites (1)
- Odense University Hospital, Odense, Denmark
Related treatments
NAD+ boosters · NR (nicotinamide riboside) · Senolytics · Quercetin